ReviewMolecules (Basel, Switzerland)2026
Emerging Plasmonic Nanomaterials for SERS-Based Disease Diagnostics: Innovations, Clinical Challenges, and AI Integration.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surface-enhanced Raman spectroscopy (SERS) has emerged as a transformative tool in biomedical diagnostics, offering a highly sensitive and non-invasive method for detecting molecular biomarkers at exceptionally low concentrations. This approach takes advantage of the plasmonic characteristics of customized metallic nanostructures that produce intense localized electromagnetic fields via localized surface plasmon resonance and facilitate electron transfer reactions that notoriously enhance the intrinsically weak Raman scattering signals of molecular entities which reside on or next to their surfaces. SERS-based assays have shown remarkable potential in detecting cancer biomarkers, circulating tumor DNA (ctDNA), and proteins at early stages, enabling timely and targeted intervention. Additionally, the combination of SERS with AI-driven data analysis has facilitated real-time diagnostics, enhancing the precision and efficiency of point-of-care testing. Despite its promising capabilities, challenges such as substrate fouling, signal degradation, and the need for better biocompatibility remain. Nevertheless, ongoing research in substrate development, coupled with advances in AI, positions SERS as a leading technology for future diagnostic tools. This paper explores the current state of SERS in biomedical applications, highlighting its potential to revolutionize diagnostics and personalized medicine while addressing the existing limitations and future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.